Free Trial
NASDAQ:ELDN

Eledon Pharmaceuticals Q1 2025 Earnings Report

Eledon Pharmaceuticals logo
$2.98 -0.05 (-1.65%)
Closing price 06/5/2025 04:00 PM Eastern
Extended Trading
$3.07 +0.09 (+3.05%)
As of 06/5/2025 04:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eledon Pharmaceuticals EPS Results

Actual EPS
-$0.08
Consensus EPS
-$0.28
Beat/Miss
Beat by +$0.20
One Year Ago EPS
N/A

Eledon Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Eledon Pharmaceuticals Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Wednesday, May 14, 2025
Conference Call Time
12:00AM ET

Upcoming Earnings

Eledon Pharmaceuticals' Q2 2025 earnings is scheduled for Monday, August 18, 2025

Eledon Pharmaceuticals Earnings Headlines

How to target 627% gains from Trump’s tweets
President Trump is shaking up the market with his tweets and Truth Social posts... But while this chaos has scared investors and Wall Street over the past few months... One ex-Chicago Exchange trader is taking a very different approach to Trump’s 2nd term. In fact, he has an incredible 80%-win rate across all of his trades in 2025 so far.
See More Eledon Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Eledon Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eledon Pharmaceuticals and other key companies, straight to your email.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals (NASDAQ:ELDN) operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

View Eledon Pharmaceuticals Profile

More Earnings Resources from MarketBeat